论文部分内容阅读
含有铝的磷酸盐结合剂通常用于治疗慢性肾衰竭患者的高磷酸盐血症,但是铝的蓄积能导致骨软化。为了评价碳酸钙代替磷酸盐结合剂的效能,本文作者对于依靠肾透析维持的20名慢性肾衰病人进行三个阶段研究。第一阶段,病人服用一个月的氢氧化铝(平均剂量5.6g/天,范围为1.5～14.0g/天)。第二阶段,病人在一个月内不服用磷酸盐结合剂。第三阶段,病人服用两个月的碳酸钙(平均剂量为8.5g/天,范围是2.5～17g/天)。第一阶段,血清钙水平的平均数(±SE)为9.6±0.2mg/dl;第二阶段血清钙水平稍有下降(9.3±0.1mg/dl);在第三阶段血清钙水平又稍有上升(10.0±
Aluminum-containing phosphate binders are commonly used to treat hyperphosphatemia in patients with chronic renal failure, but accumulation of aluminum can lead to osteomalacia. In order to evaluate the efficacy of calcium carbonate in place of phosphate binders, the authors conducted a three-phase study of 20 chronic renal failure patients on renal dialysis maintenance. In the first phase, the patient took one month of aluminum hydroxide (average dose of 5.6 g / day in the range of 1.5-14.0 g / day). In the second phase, the patient did not take phosphate binders within a month. In the third phase, the patient took two months of calcium carbonate (average dose of 8.5 g / day in the range of 2.5-17 g / day). The mean serum calcium level (± SE) was 9.6 ± 0.2 mg / dl in the first phase; the serum calcium level decreased slightly in the second phase (9.3 ± 0.1 mg / dl); in the third phase the serum calcium level was slightly Rise (10.0 ±